<SEC-DOCUMENT>0001193125-21-089541.txt : 20210322
<SEC-HEADER>0001193125-21-089541.hdr.sgml : 20210322
<ACCEPTANCE-DATETIME>20210322161317
ACCESSION NUMBER:		0001193125-21-089541
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210322
DATE AS OF CHANGE:		20210322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-250015
		FILM NUMBER:		21761432

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d152545d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-250015 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#cc062a">The information in this preliminary prospectus supplement is not complete
and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these
securities, and we are not soliciting offers to buy these securities, in any jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#cc062a"><B>PRELIMINARY PROSPECTUS SUPPLEMENT (Subject to Completion) </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#cc062a"><B>Dated March&nbsp;22, 2021 </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS SUPPLEMENT</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><B>(To Prospectus dated
November&nbsp;19, 2020)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g152545g91e59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are
offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our common stock is listed on
the Nasdaq Global Market under the symbol &#147;XGN.&#148; On March&nbsp;19, 2021, the last reported sales price of our common stock on the Nasdaq Global Market was $20.00 per share of common stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Per&nbsp;share&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Public offering price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Underwriting discounts and commissions(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Proceeds to Exagen, before expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have granted the underwriters an option for a period of 30 days to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our common
stock involves risks. See &#147;<A HREF="#suprom152545_3">Risk Factors</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-5</FONT> of this prospectus supplement and the documents incorporated by reference into this prospectus supplement.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or
adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver
the shares of common stock to purchasers on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-running Managers </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="bottom"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>William&nbsp;Blair</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Book-running Manager </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:13pt">
<TD VALIGN="top" ALIGN="center"><B>Canaccord Genuity</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Lead Manager </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:13pt">
<TD VALIGN="top" ALIGN="center"><B>BTIG</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Prospectus Supplement</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_1">About This Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_2">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_4">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_6">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_7">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_8">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_9">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#suprom152545_10">Where You Can Find More Information; Information Incorporated By
Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Prospectus</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_2">Where You Can Find More Information: Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_3">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_5">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_8">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_9">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_10">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_11">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_12">Global Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_13">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_14">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc152545_15">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Neither we nor any of the underwriters have authorized anyone to provide information different from that contained in this prospectus supplement.
When you make a decision about whether to invest in our common stock, you should not rely upon any information other than the information in this prospectus supplement. Neither the delivery of this prospectus supplement nor the sale of shares of our
common stock means that information contained in this prospectus supplement is correct after the date of this prospectus supplement. This prospectus supplement is not an offer to sell or solicitation of an offer to buy shares of our common stock in
any circumstances under which the offer or solicitation is unlawful. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus supplement and the accompanying prospectus dated November&nbsp;19, 2020 are part of a registration statement that we filed with the
Securities and Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. This prospectus supplement and the accompanying prospectus relate to the offer by us of shares of our common stock to certain investors. We provide
information to you about this offering of shares of our common stock in two separate documents that are bound together: (1)&nbsp;this prospectus supplement, which describes the specific details regarding this offering; and (2)&nbsp;the accompanying
prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this &#147;prospectus,&#148; we are referring to both documents combined. If information in this prospectus supplement is
inconsistent with the accompanying prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document
incorporated by reference in this prospectus supplement or the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations
and prospects may have changed since the earlier dates. You should read this prospectus supplement, the accompanying prospectus, the documents and information incorporated by reference in this prospectus supplement and the accompanying prospectus,
and any free writing prospectus that we have authorized for use in connection with this offering when making your investment decision. You should also read and consider the information in the documents we have referred you to under the headings
&#147;Where You Can Find More Information; Information Incorporated by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">You should rely only on information contained in or
incorporated by reference into this prospectus supplement and the accompanying prospectus. We have not, and the underwriters have not, authorized anyone to provide you with information that is different. We are offering to sell and seeking offers to
buy shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus supplement, the accompanying prospectus, the documents and information incorporated by reference in this
prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering are accurate only as of their respective dates, regardless of the time of delivery of this
prospectus supplement or of any sale of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In this prospectus supplement, unless the context otherwise indicates, the terms
&#147;Exagen,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;our&#148; and &#147;us&#148; or similar terms refer to Exagen Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We use our
trademarks in this prospectus as well as trademarks, tradenames and service marks that are the property of other organizations. Use or display by us of other parties&#146; trademarks, trade dress or products is not intended to and does not imply a
relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owner. Solely for convenience, certain trademarks and tradenames referred to in this prospectus appear without the
<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under
applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>The items in the following summary are described in more detail later in this prospectus supplement and in the accompanying prospectus. This summary
provides an overview of selected information and does not contain all the information you should consider before investing in our common stock. Therefore, you should read the entire prospectus supplement, the accompanying prospectus and any free
writing prospectus that we have authorized for use in connection with this offering carefully, including the &#147;Risk Factors&#148; section, and other documents or information included or incorporated by reference in this prospectus supplement and
the accompanying prospectus before making any investment decision. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exagen Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand, several of which
are based on our proprietary Cell-Bound Complement Activation Products, or <FONT STYLE="white-space:nowrap">CB-CAPs,</FONT> technology. <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> assess the activation of the complement system, a biological
pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis,
prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel,
targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently market 10 testing products under our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand that allow for the differential
diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD, enables differential diagnosis for patients presenting with
symptoms indicative of a wide variety of connective tissue diseases, or CTDs, and other related diseases with overlapping symptoms. The comprehensive nature of AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD allows for the
testing of a number of relevant biomarkers in one convenient blood draw, as opposed to testing serially for individual biomarkers, which adds time and cost to the diagnostic process. We believe
AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> CTD may provide clinical utility for over 23&nbsp;million patients in the United States suffering from these diseases, which include SLE, RA, Sj&ouml;gren&#146;s syndrome,
antiphospholipid syndrome, or APS, other autoimmune-related diseases such as autoimmune thyroid, and other disorders that mimic these diseases, such as fibromyalgia. There is an unmet need for rheumatologists to add clarity in their CTD clinical
evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are leveraging our portfolio of testing products to establish partnerships with leading pharmaceutical companies, academic research centers and
patient advocacy organizations. In December 2018, we entered into a <FONT STYLE="white-space:nowrap">co-promotion</FONT> agreement, or the Janssen Agreement, with Janssen Biotech, Inc., or Janssen, to exclusively promote SIMPONI<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (golimumab) in order to advance our integrated testing and therapeutics strategy, and we began direct promotion of SIMPONI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in January
2019. We also have agreements with other leading pharmaceutical companies and clinical research organizations, including GlaxoSmithKline LLC, or GSK, Covance Inc. and Parexel that leverage our testing products and/or the data generated from such
tests. We provide GSK, a leader in lupus </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
therapeutics, our test result data to provide market insight into and help increase awareness of the benefits of an early and accurate diagnosis of SLE and lupus nephritis, and monitoring disease
activity. We partner with academic research centers and patient advocacy organizations, such as Brigham and Women&#146;s Hospital, Hospital for Special Surgery, and Duke University as well as the Lupus Foundation of America, to help improve the
quality of life for people affected by autoimmune diseases through programs of research, education, support and advocacy. We plan to pursue additional partnerships that are synergistic with our evolving portfolio of testing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have demonstrated a strong track record of developing innovative testing products that meet the needs of diagnosing, prognosing and monitoring CTDs,
as illustrated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g152545g06a48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Exclusive Forum Provision </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective as of March&nbsp;22, 2021, our Board of Directors adopted an amendment and restatement of our bylaws pursuant to which a new Article XI was
added, which provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Corporate Information </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, we changed our state of incorporation
from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which we changed our name to Exagen Diagnostics, Inc. In January 2019, we changed our name to Exagen Inc. Our principal executive offices are located at 1261
Liberty Way, Vista, California 92081. Our telephone number is (760) <FONT STYLE="white-space:nowrap">560-1501.</FONT> Our website address is www.exagen.com. The information on, or accessible through, our website is not part of, and is not
incorporated into, this prospectus supplement or the accompanying prospectus and should not be considered part of this prospectus supplement or the accompanying prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option exercisable for a period of 30 days after the date of this prospectus supplement to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common
stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise in full their option to purchase additional shares of
our common stock in full) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We currently intend to use the net proceeds from this offering for the development of Multi-omics capabilities, including build out of our clinical laboratory, advancement of our product pipeline, including to support development of tests for
fibromyalgia, RA, thrombosis and lupus nephritis, enhancement of intellectual property protection for our technologies, and for working capital and other general corporate purposes. We may also use a portion of the net proceeds to <FONT
STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets; however, we have no current commitments or obligations to do so. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to invest in our common
stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Nasdaq Global Market symbol </P></TD>
<TD>&#147;XGN&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares of common stock to be outstanding after this offering is based on 12,652,308 shares
outstanding as of December&nbsp;31, 2020, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,975,761 shares of common stock issuable upon the exercise of stock options outstanding as of December&nbsp;31, 2020 under
our equity incentive plans, with a weighted average exercise price of $11.81 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">426,827 shares of common stock issuable upon the exercise of warrants outstanding as of December&nbsp;31, 2020, with a
weighted-average exercise price of $4.90 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">185,000 shares of common stock reserved for issuance upon the vesting of outstanding restricted stock units granted after
December&nbsp;31, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,139,323 shares of common stock reserved for future issuance under our 2019 Incentive Award Plan as of December&nbsp;31,
2020; and </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">233,961 shares of common stock reserved for future issuance under our 2019 Employee Stock Purchase Plan as of
December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Except as otherwise indicated, all information in this prospectus supplement assumes no exercise of
outstanding options and no exercise by the underwriters of their option to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>You should consider carefully the risks described below and discussed under the section captioned &#147;Risk Factors&#148; contained in our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020 as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are incorporated by
reference in this prospectus supplement and the accompanying prospectus in their entirety, together with other information in this prospectus supplement, the accompanying prospectus and the information and documents incorporated by reference in this
prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering before you make a decision to invest in our common stock. If any of the following events actually
occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose all or part of your investment. The risks
described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business operations. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Relating to This Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If you purchase shares of our common
stock sold in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares. In addition, we may issue additional equity or convertible debt securities in the future, which may result in
additional dilution to investors. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The offering price per share of common stock in this offering is considerably more than the net tangible
book value per share of our outstanding common stock. As a result, investors purchasing shares of common stock in this offering will pay a price per share that substantially exceeds the value of our tangible assets after subtracting liabilities.
Based upon the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, new investors will incur immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share based on the net tangible book value as of December&nbsp;31, 2020. For a more detailed discussion of the foregoing, see the section entitled &#147;Dilution&#148; below. To the extent outstanding stock options are exercised, there will be
further dilution to new investors. In addition, to the extent we need to raise additional capital in the future and we issue additional shares of common stock or securities convertible or exchangeable for our common stock, our then existing
stockholders may experience dilution and the new securities may have rights senior to those of our common stock offered in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our management team
may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant return. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the
section entitled &#147;Use of Proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will
determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. We
expect to use the net proceeds from this offering for the development of Multi-omics capabilities, including build out of our clinical laboratory, advancement of our product pipeline, including to support development of tests for fibromyalgia, RA,
thrombosis and lupus nephritis, enhancement of intellectual property protection for our technologies, and for working capital and other general corporate purposes. We may also use a portion of the net proceeds to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets; however, we have no current commitments or obligations to do so. The failure by our management to apply these funds
effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do
not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, and any free writing
prospectus that we have authorized for use in connection with this offering contain forward-looking statements within the meaning of Section&nbsp;21E of the Exchange Act. All statements other than statements of historical facts contained in this
prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein are forward-looking statements, including statements regarding our future results of operations and financial position, business strategy, the
impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, current and future product offerings, reimbursement and coverage, our ability to implement an integrated testing with therapeutics strategy, the expected benefits from our
partnership or promotion arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements involve known
and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and
other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future
performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In some cases, you can identify
forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148;
&#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus
supplement, the accompanying prospectus and the documents incorporated by reference herein are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial
trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus supplement and are subject to a number of risks, uncertainties and
assumptions, which we discuss in greater detail in the documents incorporated by reference herein, including under the heading &#147;Risk Factors.&#148; Because forward-looking statements are inherently subject to risks and uncertainties, some of
which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may
not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is
not possible for management to predict all risk factors and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly
update or revise any forward-looking statements contained in this prospectus supplement, the accompanying prospectus or the documents incorporated by reference herein, whether as a result of any new information, future events, changed circumstances
or otherwise. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that we will receive net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million from the
sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock offered by us in this offering, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the
underwriters exercise in full their option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently intend to use the net proceeds of this offering for the development of Multi-omics
capabilities, including build out of our clinical laboratory, advancement of our product pipeline, including to support development of tests for fibromyalgia, RA, thrombosis and lupus nephritis, enhancement of intellectual property protection for
our technologies, and for working capital and other general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may also use a portion of the net proceeds to <FONT
STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The amounts and timing of our actual expenditures will depend on numerous factors, including the factors described under &#147;Risk Factors&#148; in
this prospectus supplement and in the documents incorporated by reference herein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad
discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of
deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_6"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per
share and the net tangible book value per share of our common stock after this offering. As of December&nbsp;31, 2020, our net tangible book value was $36.3&nbsp;million, or $2.87 per share, based on 12,652,308 shares of our common stock outstanding
as of December&nbsp;31, 2020. Our net tangible book value per share represents the amount of our total tangible assets reduced by the amount of our total liabilities, divided by the total number of shares of our common stock outstanding as of
December&nbsp;31, 2020. After giving effect to our sale in this offering of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock at the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our net tangible book value as of
December&nbsp;31, 2020 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in
net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share
to new investors purchasing our common stock in this offering. The following table illustrates this per share dilution. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net tangible book value per share at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase per share attributable to investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">As adjusted net tangible book value per share, after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to investors purchasing our common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the underwriters exercise in full their option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share,
representing an immediate increase in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
foregoing tables and calculations (other than net tangible book value calculations) are based on 12,652,308 shares outstanding as of December&nbsp;31, 2020, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,975,761 shares of common stock issuable upon the exercise of stock options outstanding as of December&nbsp;31, 2020 under
our equity incentive plans, with a weighted average exercise price of $11.81 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">185,000 shares of common stock reserved for issuance upon the vesting of outstanding restricted stock units granted after
December&nbsp;31, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">426,827 shares of common stock issuable upon the exercise of warrants outstanding as of December&nbsp;31, 2020, with a
weighted-average exercise price of $4.90 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,139,323 shares of common stock reserved for future issuance under our 2019 Incentive Award Plan as of December&nbsp;31,
2020; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">233,961 shares of common stock reserved for future issuance under our 2019 Employee Stock Purchase Plan as of
December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To the extent that outstanding options are exercised, you may experience further dilution. In addition,
we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital by issuing equity or
convertible debt securities, your ownership will be further diluted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_7"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the common stock being offered. Subject
to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of shares of our common stock set forth opposite its name below. Cowen and Company, LLC, William Blair&nbsp;&amp;
Company, L.L.C. and Cantor Fitzgerald&nbsp;&amp; Co. are the representatives of the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Canaccord Genuity LLC.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">BTIG, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent
and that the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the option to purchase additional shares
described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to
contribute to payments the underwriters may be required to make in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters are offering the shares, subject to prior
sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the
public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Discounts and Commissions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table shows the public offering price, underwriting discount and proceeds, before expenses to us. These amounts are shown assuming both no
exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that the total expenses of the offering,
excluding underwriting discount, will be approximately $250,000 and are payable by us. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $30,000. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>shares<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>shares<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters propose to offer the shares of common stock to the public at the public offering price set forth on the
cover of this prospectus. The underwriters may offer the shares of common stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to securities dealers at the public offering price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share.
If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase
Additional Shares </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have granted to the underwriters an option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock at the public offering price, less the underwriting discount. This option is exercisable for a period of 30 days. To the extent
that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Discretionary Accounts </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters do not intend to
confirm sales of the shares to any accounts over which they have discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NASDAQ Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares are listed on the Nasdaq Global Market under the symbol &#147;XGN.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization, Short Positions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this
offering, the underwriters may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a
specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Overallotment transactions involve sales by the underwriters of shares of common stock in excess of the number of shares
the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not
greater than the number of shares that they may purchase in the option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares in the option to purchase additional shares. The
underwriters may close out any short position by exercising their option to purchase additional shares and/or purchasing shares in the open market. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been
completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared
with the price at which they may purchase shares through exercise of the option to purchase additional shares. If the underwriters sell more shares than could be covered by exercise of the option to purchase additional shares and, therefore, have a
naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of
the shares in the open market that could adversely affect investors who purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock
originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect
of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in
the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on the
Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the New York Stock Exchange, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be
discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Offer, Sale and Distribution of Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any,
participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a number of shares to underwriters and selling group members for
sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in
electronic format, the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and
should not be relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Passive Market Making </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the
Nasdaq Global Market in accordance with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of common stock and extending through the completion of the distribution. A passive market maker must
display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, such bid must then be lowered when specified purchase limits are
exceeded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to certain <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, we and our executive officers, directors and certain of our
securityholders affiliated with our directors have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any
swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic consequence of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file
with the SEC a registration statement under the Securities Act relating to, any common stock or securities convertible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
into or exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC, William Blair&nbsp;&amp; Company, L.L.C. and Cantor Fitzgerald &amp; Co., for
a period of 90 days after the date of the pricing of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common
stock and to securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later
acquires the power of disposition. The <FONT STYLE="white-space:nowrap">lock-up</FONT> provision will not restrict broker-dealers from engaging in market making and similar activities conducted in the ordinary course of their business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain of the underwriters and their
affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of
their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of
customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling Restrictions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In relation to each Member State of the European Economic Area (each, a &#147;Member State&#148;), no shares have been offered or will be offered
pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member
State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that shares may be offered to the public in that Member State at any time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A.&nbsp;&nbsp;&nbsp;&nbsp;to any legal entity which is a qualified investor as defined under Article 2 the Prospectus Regulation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">B.&nbsp;&nbsp;&nbsp;&nbsp;to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">C.&nbsp;&nbsp;&nbsp;&nbsp;in any other
circumstances falling within Article 1(4) of the Prospectus Regulation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require us or any of the
representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to shares in any Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means
Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in
relation to the shares which has been approved by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A. &nbsp;&nbsp;&nbsp;&nbsp;to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">B. &nbsp;&nbsp;&nbsp;&nbsp;to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">C. &nbsp;&nbsp;&nbsp;&nbsp;in any other
circumstances falling within Section&nbsp;86 of the FSMA, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">provided that no such offer of the shares shall require the Issuer or any Manager to
publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the
shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the
expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Switzerland </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares
will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in France </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus
has not been prepared in the context of a public offering of financial securities in France within the meaning of Article <FONT STYLE="white-space:nowrap">L.411-1</FONT> of the French Code Mon&eacute;taire et Financier and Title I of Book II of the
Reglement G&eacute;n&eacute;ral of the Autorit&eacute; des march&eacute;s financiers, or the AMF, and therefore has not been and will not be filed with the AMF for prior approval or submitted for clearance to the AMF. Consequently, the shares of our
common stock may not be, directly or indirectly, offered or sold to the public in France and offers and sales of the shares of our common stock may only be made in France to qualified investors (investisseurs qualifi&eacute;s) acting for their own,
as defined in and in accordance with Articles <FONT STYLE="white-space:nowrap">L.411-2</FONT> and <FONT STYLE="white-space:nowrap">D.411-1</FONT> to <FONT STYLE="white-space:nowrap">D.411-4,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT
STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the French Code Mon&eacute;taire et Financier. Neither this prospectus nor any other offering material
may be released, issued or distributed to the public in France or used in connection with any offer for subscription on sale of the shares of our common stock to the public in France. The subsequent direct or indirect retransfer of the shares of our
common stock to the public in France may only be made in compliance with Articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT
STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the French Code Mon&eacute;taire et Financier.. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Germany </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each person who
is in possession of this prospectus is aware of the fact that no German securities prospectus (wertpapierprospekt) within the meaning of the securities prospectus act (wertpapier-prospektgesetz), or the act, of the federal republic of Germany has
been or will be published with respect to the shares of our common stock. In particular, each underwriter has represented that it has not engaged and has agreed that it will not engage in a public offering in the federal republic of Germany
(&ocirc;ffertliches angebot) within the meaning of the act with respect to any of the shares of our common stock otherwise than in accordance with the act and all other applicable legal and regulatory requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in The Netherlands </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The offering of the shares of our common stock is not a public offering in The Netherlands. The shares of our common stock may not be offered or sold to
individuals or legal entities in The Netherlands unless (i)&nbsp;a prospectus relating to the offer is available to the public, which has been approved by the Dutch Authority for the Financial Markets (Autoriteit Financi&euml;le Markten) or by the
competent supervisory authority of another state that is a member of the European Union or party to the Agreement on the European Economic Area, as amended or (ii)&nbsp;an exception or exemption applies to the offer pursuant to Article 5:3 of The
Netherlands Financial Supervision Act (Wet op het financieel toezicht) or Article 53 paragraph 2 or 3 of the Exemption Regulation of the Financial Supervision Act, for instance due to the offer targeting exclusively &#147;qualified investors&#148;
(gekwalificeerde beleggers) within the meaning of Article 1:1 of The Netherlands Financial Supervision Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Hong Kong
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#147;SFO&#148;) of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the
document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the &#147;CO&#148;), or which do not constitute an offer to the public within the meaning of the CO. No
advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which
are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or
only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) and,
accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to any Japanese
Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese
Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective
Investors in Singapore </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary
Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any
shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the
offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A.
&nbsp;&nbsp;&nbsp;&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of the
SFA; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">B. &nbsp;&nbsp;&nbsp;&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA)
pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">C. &nbsp;&nbsp;&nbsp;&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A. &nbsp;&nbsp;&nbsp;&nbsp;a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is
to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">B.
&nbsp;&nbsp;&nbsp;&nbsp;a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and
interest (however described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(i) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or
Section&nbsp;276(4)(i)(B) of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(ii) where no consideration is or will be given for the transfer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(iii) where the transfer is by operation of law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(iv) as specified in Section&nbsp;276(7) of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(v) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts)
Regulations 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless
otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP
Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on
Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National
Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT>
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the
securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to
section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT
STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The validity of the issuance of the securities offered hereby will be passed upon by our counsel, Latham&nbsp;&amp; Watkins LLP, San Diego, California.
The underwriters are being represented in connection with this offering by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_9"></A>EXPERTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
financial statements as of December&nbsp;31, 2020 and 2019 and for the years then ended incorporated by reference in this prospectus supplement have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public
accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="suprom152545_10">
</A>WHERE YOU CAN FIND MORE INFORMATION; INFORMATION INCORPORATED BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Available Information </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, of which this
prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For further information about us
and the securities we are offering under this prospectus supplement, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus
supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed
as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We file reports, proxy statements and other information with the SEC. The SEC maintains a website that
contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our website address is www.exagen.com. The information on, or accessible through, our website is not part of, and is not incorporated into, this
prospectus supplement or the accompanying prospectus and should not be considered part of this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Incorporation by Reference </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The SEC&#146;s rules allow us to
&#147;incorporate by reference&#148; information into this prospectus supplement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by
reference is deemed to be part of this prospectus supplement and the accompanying prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in a previously
filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying prospectus to the extent that a statement contained in this prospectus supplement or the
accompanying prospectus modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We incorporate by reference our documents listed below and any future filings made by
us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus supplement and the termination of the offering of the securities described in this prospectus supplement. We are not, however,
incorporating by reference any documents or portions thereof, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
whether specifically listed below or filed in the future, that are not deemed &#147;filed&#148; with the SEC, including our Compensation Committee report and performance graph or any information
furnished pursuant to Items 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or related exhibits furnished pursuant to Item 9.01 of <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus supplement and the accompanying prospectus incorporate by reference the documents set forth below that have previously been filed with
the SEC: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1274737/000127473721000015/exdx-20201231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;16, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000031/a2020def14a.htm">Schedule
 14A</A> (other than information furnished rather than filed), filed with the SEC on April&nbsp;29, 2020; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the description of our Common Stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519244881/d756255d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on September&nbsp;13, 2019 and any amendment or report filed with the SEC for the purpose of updating the description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All reports and other documents we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of
this offering, including, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement and the accompanying prospectus and deemed to be part of this prospectus
supplement and the accompanying prospectus from the date of the filing of such reports and documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">You may request a free copy of any of the
documents incorporated by reference in this prospectus supplement and the accompanying prospectus (other than exhibits, unless they are specifically incorporated by reference in the documents) by writing or telephoning us at the following address:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Exagen Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Attention: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1261 Liberty Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Vista, California 92081 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(760) <FONT STYLE="white-space:nowrap">560-1501</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g152545g91e59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$150,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="font-size:15pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:15pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell up to $150.0&nbsp;million in the aggregate of the securities identified above from time to time in one or more
offerings. This prospectus provides you with a general description of the securities. </P> <P STYLE="margin-top:15pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities, we will
provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to
that offering. You should carefully read this prospectus and the applicable prospectus supplement, together with the documents we incorporate by reference before you invest in any of our securities. </P>
<P STYLE="margin-top:15pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters,
dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or
discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled &#147;About this Prospectus&#148; and
&#147;Plan of Distribution&#148; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities. </P>
<P STYLE="font-size:15pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:15pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#147;<A HREF="#toc152545_4">RISK FACTORS</A>&#148; ON PAGE 4 OF THIS PROSPECTUS AND
ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES. </B></P>
<P STYLE="margin-top:15pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;XGN.&#148; On November&nbsp;9, 2020, the last reported
sale price of our common stock on The Nasdaq Global Select Market was $15.55 per share. </P> <P STYLE="margin-top:15pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:15pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is November&nbsp;19, 2020. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_8">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_10">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_11">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_12">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_13">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_14">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc152545_15">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a
&#147;shelf&#148; registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount of $150.0&nbsp;million as described in this prospectus. Each time that
we offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free
writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus with respect
to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable.
Before purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the heading
&#147;Where You Can Find More Information; Incorporation by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any
information or to make any representations other than those contained in this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should
assume that the information appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is
accurate only as of the date of that free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial
condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry
statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have
not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and
uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in this prospectus, the applicable prospectus supplement and any applicable free writing prospectus, and
under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we refer to &#147;Exagen,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus, we mean
Exagen Inc., unless otherwise specified. When we refer to &#147;you,&#148; we mean the holders of the applicable series of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
use our trademarks in this prospectus as well as trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, certain trademarks and tradenames referred to in this prospectus appear without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under
applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_2"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file
reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of
that website is <I>http://www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is www.exagen.com. The information on our website, however, is not, and
should not be deemed to be, a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration statement
that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the indenture and other documents establishing the
terms of the offered securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are
summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration
statement through the SEC&#146;s website, as provided above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by Reference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will
automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a
statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
incorporate by reference our documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the &#147;Exchange Act&#148; in this
prospectus, between the date of this prospectus and the termination of the offering of the securities described in this prospectus. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed below
or filed in the future, that are not deemed &#147;filed&#148; with the SEC, including our Compensation Committee report and performance graph or any information furnished pursuant to Items 2.02 or 7.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> or related exhibits furnished pursuant to Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> This prospectus and any accompanying prospectus supplement incorporate by reference the documents
set forth below that have previously been filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1274737/000127473720000026/exdx-20191231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;25, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended March&nbsp;31,
2020, June&nbsp;30, 2020 and September&nbsp;30, 2020, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1274737/000127473720000037/exdx-20200331.htm">May&nbsp;
11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1274737/000127473720000077/exdx-20200630.htm">July&nbsp;
28, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1274737/000127473720000097/exdx-20200930.htm">November&nbsp;10, 2020</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000031/a2020def14a.htm">Schedule
 14A</A> (to the extent incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K),</FONT> filed with the SEC on April&nbsp;29, 2020; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000016/xgn8-kxleaseagreementa.htm">March&nbsp;18,
 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000040/xgn8-kxannualmeetingre.htm">June&nbsp;
19, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000043/xgn8-kxjanssenamendmen.htm">June&nbsp;
29, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000080/xgn8-kxdirectorappoint.htm">September&nbsp;23, 2020</A>; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1274737/000119312519244881/d756255d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on September&nbsp;13, 2019, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All reports and other documents we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the
termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather
than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of the documents incorporated by reference in this prospectus (other than exhibits, unless they are
specifically incorporated by reference in the documents) by writing or telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exagen Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1261 Liberty Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Vista, California
92081 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(760) <FONT STYLE="white-space:nowrap">560-1501</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus
or any accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling
timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brand, several of
which are based on our proprietary Cell-Bound Complement Activation Products, or <FONT STYLE="white-space:nowrap">CB-CAPs,</FONT> technology. <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> assess the activation of the complement system, a
biological pathway that is widely implicated across many autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential
diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE, and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market
therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and,
ultimately, better serve patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the state of New Mexico in 2002, under the name Exagen
Corporation. In 2003, we changed our state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which we changed our name to Exagen Diagnostics, Inc. In January 2019 we changed our name to
Exagen Inc. Our principal executive offices are located at 1261 Liberty Way, Vista, California 92081. Our telephone number is (760) <FONT STYLE="white-space:nowrap">560-1501.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully
consider the risk factors incorporated by reference to our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the
risk factors and other information contained in the applicable prospectus supplement before acquiring any such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein contain forward-looking statements within the meaning of Section&nbsp;21E
of the Exchange Act. All statements other than statements of historical facts contained in this prospectus and the documents incorporated by reference herein, including statements regarding our future results of operations and financial position,
business strategy, current and future product offerings, reimbursement and coverage, our ability to implement an integrated testing with therapeutics strategy, the expected benefits from our partnership or promotion arrangements with third parties,
research and development costs, timing and likelihood of success, plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This prospectus and the documents incorporated by
reference herein also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are
cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty
and risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148;
&#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148;
&#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus and the documents incorporated by reference herein are only
predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These
forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions, which we discuss in greater detail in the documents incorporated by reference herein, including under the
heading &#147;Risk Factors&#148; and elsewhere in this prospectus. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the
forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Given these risks and
uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this prospectus or the documents
incorporated by reference herein, whether as a result of any new information, future events, changed circumstances or otherwise. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation
of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition,
results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, our ability to pay cash dividends is
currently prohibited by the terms of our loan and security agreement with Innovatus Life Science Lending Fund I, LP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_8"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description
summarizes some of the terms of capital stock. Because it is only a summary, it does not contain all the information that may be important to you and is subject to and qualified in its entirety by reference to our amended and restated certificate of
incorporation (the &#147;certificate of incorporation&#148;) and amended and restated bylaws (the &#147;bylaws&#148;), which are filed as exhibits to our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and are
incorporated by reference herein. We encourage you to read our certificate of incorporation and our bylaws for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 200,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred
stock, $0.001 par value per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, there were 12,652,113 shares of our common stock outstanding and held of record by 50 stockholders. Holders of
our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the
outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to
elect. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such
matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT>
in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably
those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally
available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of common stock have no preemptive or conversion
rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be outstanding upon the closing of this offering will be,
duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock
that we may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is
250 Royall Street, Canton, Massachusetts 02021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, there were no shares of our preferred stock outstanding. Under the terms of our amended and restated certificate
of incorporation, our board of directors has the authority, without further action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the
dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not
below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with
voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate
purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have
no current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the issuance of shares of each series, the board of directors is
required by the General Corporation Law of the State of Delaware, or the DGCL, and our amended and restated certificate of incorporation to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Delaware.
The certificate of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions, including dividend rights, conversion rights, redemption privileges and liquidation
preferences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of preferred stock offered by this prospectus will, when issued, be fully paid and nonassessable and will not
have any preemptive or similar rights. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The
issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely
affect the market price of the common stock and the voting and other rights of the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in a
prospectus supplement relating to the class or series of preferred stock being offered the following terms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of the preferred stock offered, the liquidation preference per share and the offering price
of the preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate(s), period(s) or payment date(s) or method(s) of calculation applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends are cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if cumulative,
the date from which dividends on the preferred stock will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any, for the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any, for the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provision for redemption, if applicable, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock,
including the conversion price or manner of calculation and conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the
liquidation, dissolution or winding up of our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the
class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we specify otherwise in the applicable prospectus supplement, the preferred stock will rank, relating to
dividends and upon our liquidation, dissolution or winding up: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to all classes or series of our common stock and to all of our equity securities ranking junior to the
preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a parity with all of our equity securities the terms of which specifically provide that the equity securities
rank on a parity with the preferred stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">junior to all of our equity securities the terms of which specifically provide that the equity securities rank
senior to the preferred stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term equity securities does not include convertible debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020,
426,827 shares of our common stock were issuable upon exercise of outstanding warrants to purchase common stock with a weighted average exercise price of $4.90 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the above warrants has a net exercise provision under which the holder may, in lieu of payment of the exercise price in cash,
surrender the warrant and receive a net amount of shares of our common stock based on the fair market value of our common stock at the time of the net exercise of the warrant after deduction of the aggregate exercise price. These warrants also
contain provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon the exercise of the warrants in the event of stock dividends, stock splits, reorganizations and reclassifications and consolidations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2020, holders of 6,042,679 shares of our common stock, are entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to an investor rights agreement by
and among us and certain of our stockholders. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable
registration statement is declared effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Form <FONT STYLE="white-space:nowrap">S-1.</FONT> </I>If at any time holders of at least 50% of the registrable securities request in
writing that we effect a registration with respect to their shares in an offering, we may be required to register their shares. We are obligated to effect at most two registrations for the holders of registrable securities in response to these
demand registration rights, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Form S-</I>3. If at any time, a holder of registrable securities requests
in writing that we register their shares for public resale on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and the price to the public of the offering is $1.0&nbsp;million or more, we will be required to provide notice to all holders of
registrable securities and to use our best efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, within the preceding 12 months, we have already effected two registrations on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each of the above registrations, if the holders requesting registration intend to
distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any
time we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable
securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than
underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees,
printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders, blue sky fees and expenses and the expenses of any special audits incident to the registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
registration rights terminate upon the earlier of September&nbsp;20, 2022, or for any particular holder with registration rights, at such time following this offering when such holder holds less than one percent of our outstanding common stock and
may immediately sell all of such shares pursuant to Rule 144 under the Securities Act in a <FONT STYLE="white-space:nowrap">90-day</FONT> period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions
that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that
these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium
over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and
inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to
negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability
of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any
attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Meetings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive
officer or president, or by a resolution adopted by a majority of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Requirements for Advance Notification of Stockholder
Nominations and Proposals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to
be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Elimination of Stockholder Action by Written Consent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written
consent without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Staggered Board </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected
each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for
stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our
stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholders Not Entitled to Cumulative Voting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors.
Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our
preferred stock may be entitled to elect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Statute </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#147;interested
stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction
in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or
within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction
resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Choice of Forum </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forum for: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors,
officers, employees or agents to us or our stockholders, creditors or other constituents; (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our amended and
restated certificate of incorporation or amended and restated bylaws; (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (v)&nbsp;any action asserting a claim governed by the
internal affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive
jurisdiction. To the extent that any such claims may be based upon federal law claims, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or
the rules and regulations thereunder. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules
and regulations thereunder. In any case, stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other
companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our amended and restated certificate of incorporation
and amended and restated bylaws also provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of Charter Provisions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding
voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws
could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover
attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise
deem to be in their best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_9"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement or free writing
prospectus, summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a
supplement to this prospectus. We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. To the extent the information contained in the
prospectus supplement differs from this summary description, you should rely on the information in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations
and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one or more series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a trustee named in the prospectus supplement. We have summarized select
portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In the summary below,
we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each series of debt
securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in a resolution of our board of directors, in an officer&#146;s certificate or by a supplemental indenture.
(Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating to such series (including any pricing supplement or term sheet). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue an unlimited amount of debt securities under the indenture that may be in one or more series with the same or various maturities,
at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being offered, the aggregate principal amount and the
following terms of the debt securities, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and ranking of the debt securities (including the terms of any subordination provisions);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal on a particular series of debt securities is payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the
method of such payment), where the debt securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may
redeem the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and the terms and conditions upon which the debt securities of a particular series shall be redeemed or purchased, in
whole or in part, pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities, which may be U.S. dollars or any foreign currency, and if
such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of, and premium and
interest on, the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, or premium or interest on, the debt securities will be made in one or more
currencies or currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, and premium, if any, and interest on, the debt
securities will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture
with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with
respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if
applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including
the terms of subordination, if any, of such guarantees. (Section 2.2) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal
amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any
of these debt securities in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a
foreign currency or currencies or a foreign currency unit or units, or if the principal of, and premium, if any, and interest on, any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we
will provide you with information on the restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or
units in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company (DTC or
the Depositary) or a nominee of the Depositary (we will refer to any debt security represented by a global debt security as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (we will refer to any debt
security represented by a certificated security as a &#147;certificated debt security&#148;) as set forth in the applicable prospectus supplement. Except as set forth under the heading &#147;Global Debt Securities and Book-Entry System&#148; below,
book-entry debt securities will not be issuable in certificated form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certificated Debt Securities. You may transfer or exchange
certificated debt securities at any office we maintain for this purpose in accordance with the terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require
payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange. (Section 2.7) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated
debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new
holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will be deposited
with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see the section entitled &#147;Global Securities&#148; for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the
applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities. (Article IV) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a
Change of Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any
provisions that may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) that could adversely
affect holders of debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to, any
person (a &#147;successor person&#148;) unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving corporation or the successor person (if other than Exagen) is a corporation organized and
validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be
continuing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other conditions are met. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us. (Section
5.1) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Event
of Default&#148; means with respect to any series of debt securities, any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the <FONT STYLE="white-space:nowrap">30-day</FONT> period);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any debt security of that series at its maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture or any debt
security (other than a covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written
notice from the trustee or Exagen and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Exagen; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other Event of Default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement. (Section 6.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Event of Default with respect to a particular series of debt
securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an
acceleration under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide the trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such
Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action we are taking or propose to take in respect thereof. (Section 6.1) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the
holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if the
debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount)
of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time
after a declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the
outstanding debt securities of that series may rescind and annul the acceleration if all Events of Default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest, if any, with respect to debt
securities of that series, have been cured or waived as provided in the indenture. (Section 6.2) We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions relating
to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture, unless the trustee receives indemnity satisfactory to it against any cost, liability or expense that might be incurred by
it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the
time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the
indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the
outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive
payment of the principal of, and premium and any interest on, that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section 6.8) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the
indenture. (Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each holder of the securities of
that series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold
notice to the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that
withholding notice is in the interest of the holders of those debt securities. (Section 7.5) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any
debt security: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with covenants in the indenture described above under the heading &#147;Consolidation, Merger and Sale
of Assets;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated securities in addition to or in place of certificated securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to surrender any of our rights or powers under the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants or Events of Default for the benefit of the holders of debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the applicable procedures of the applicable depositary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to
or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act. (Section 9.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also modify and amend the indenture with the consent of the holders of at
least a majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of,
or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a Default or Event of Default in the payment of the principal of, or premium or interest on, any debt
security (except a rescission of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that
resulted from such acceleration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of, or premium or interest on, any debt security payable in currency other than that stated in
the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, and premium and interest on, those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. (Section 9.3) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any
series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its
consequences, except a default in the payment of the principal of, premium or any interest on, any debt security of that series; provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series
may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration. (Section 6.13) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance
of Debt Securities and Certain Covenants in Certain Circumstances </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. The indenture provides that, unless
otherwise provided by the terms of the applicable series of debt securities, we may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the deposit
with the trustee, in trust, of money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. dollars, government obligations of the government that issued or caused to be issued such
currency, that, through the payment of interest and principal in accordance with their terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants
or investment bank to pay and discharge each installment of principal of, premium and interest on, and any mandatory sinking fund payments in respect of, the debt securities of that series on the stated maturity of those payments in accordance with
the terms of the indenture and those debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the
trustee an opinion of counsel stating that we have received from, or there has been published by, the U.S. Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal
income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the
deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3)
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of
debt securities, upon compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#147;Consolidation, Merger and Sale of
Assets&#148; and certain other covenants set forth in the indenture, as well as any additional covenants that may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to
the debt securities of that series (&#147;covenant defeasance&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide
money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on, and any mandatory sinking fund payments
in respect of, the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
amounts and in the same manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4) </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal Liability of Directors, Officers, Employees or Securityholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our past, present or future directors, officers, employees or securityholders, as such, will have any liability for any of our
obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and
release is part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against
public policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the debt securities, will be governed by the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities)
irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions
contemplated thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of
the debt securities (by their acceptance of the debt securities) irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide
that service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#146;s address set forth in the indenture will be effective service of process for any suit, action
or other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the
laying of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.
(Section 10.10) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_10"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants
independently or together with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors
or a warrant agent. The following summary of material provisions of the warrants and warrant agreements is subject to, and qualified in its entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a
particular series of warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as
the complete warrant agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of
warrants will be described in the prospectus supplement relating to the issue. Those terms may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase
such shares and the price at which such number of shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and
voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common
stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal income tax consequences applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange,
exercise and settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vote, consent or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders of Exagen. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common
stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to
the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of
transfer and exercise them at the corporate trust office of the warrant agent or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the holder of the warrants will not have any rights of holders of the
debt securities that can be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase
common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution
or winding up on the common stock or preferred stock, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_11"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may
evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and
address of the unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description,
together with the additional information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing
prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and
provisions and we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered
under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus
supplement, including, without limitation, the following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain U.S. federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_12"></A>GLOBAL SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry, Delivery and Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
indicate differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global
securities. The global securities will be deposited with, or on behalf of DTC and registered in the name of Cede&nbsp;&amp; Co., the nominee of DTC. Unless and until it is exchanged for individual certificates evidencing securities under the limited
circumstances described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the depositary or its nominee to a successor depositary or to a nominee of the
successor depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;banking organization&#148; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing agency&#148; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants
of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#146; accounts, thereby eliminating the need for physical movement of securities certificates.
&#147;Direct participants&#148; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp;
Clearing Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated
subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules
applicable to DTC and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases of securities under the DTC system must be made by or through
direct participants, which will receive a credit for the securities on DTC&#146;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and
indirect participants&#146; records. Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions,
as well as periodic statements of their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of
participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of
DTC&#146;s partnership nominee, Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee
will not change the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#146;s records reflect only the identity of the direct participants to whose accounts the securities are
credited, which may or may not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the securities are in book-entry form, you will receive payments and may transfer
securities only through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands
in respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct
participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#146;s practice is
to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither DTC
nor Cede&nbsp;&amp; Co. (or such other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the
consenting or voting rights of Cede&nbsp;&amp; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered
owner of such securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and unless if otherwise provided in the description of the applicable
securities herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in
writing to the applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede&nbsp;&amp; Co., or such other nominee as may
be requested by an authorized representative of DTC. DTC&#146;s practice is to credit direct participants&#146; accounts upon DTC&#146;s receipt of funds and corresponding detail information from us on the payment date in accordance with their
respective holdings shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered
in &#147;street name.&#148; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend
payments to Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility; disbursement of payments to direct participants is the responsibility of DTC; and disbursement of payments to
the beneficial owners is the responsibility of direct and indirect participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except under the limited circumstances described below,
purchasers of securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise
any rights under the securities and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions may require that some purchasers of securities take
physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing its services as securities depositary with respect to the securities at any time by giving reasonable notice to
us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be printed and delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, beneficial owners of a particular series of securities generally will not
receive certificates representing their ownership interests in those securities. However, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities
representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or
of our becoming aware of DTC&#146;s ceasing to be so registered, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Event of Default has occurred and is continuing with respect to such series of securities,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any
beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is
expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Euroclear and Clearstream </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so provided
in the applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we refer to as &#147;Clearstream,&#148; or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we refer to
as &#147;Euroclear,&#148; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their
respective participants through customers&#146; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#146; securities
accounts in such depositaries&#146; names on DTC&#146;s books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clearstream and Euroclear are securities clearance systems in Europe.
Clearstream and Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their accounts,
thereby eliminating the need for physical movement of certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments, deliveries, transfers, exchanges, notices and other matters
relating to beneficial interests in global securities owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and other
participants in DTC, on the other hand, are also subject to DTC&#146;s rules and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors will be able to make and receive
through Euroclear and Clearstream payments, deliveries, transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems may not
be open for business on days when banks, brokers and other institutions are open for business in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cross-market
transfers between participants in DTC, on the one hand, and participants in Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be,
by their respective U.S. depositaries; however, such cross-market transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and
within the established deadlines (European time) of such system. Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final
settlement on its behalf by delivering or receiving interests in the global securities through DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement.
Participants in Euroclear or Clearstream may not deliver instructions directly to their respective U.S. depositaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to time zone differences, the securities accounts of a participant in Euroclear or
Clearstream purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing
day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in
Euroclear or Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream
following DTC&#146;s settlement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been
obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely
within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are
urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters. In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any
obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear
or their respective participants of these or any other rules or procedures governing their respective operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_13"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the
method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers
to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as
principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with
the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the
purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best
efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or
commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the
meaning of the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify
underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any common stock will be listed on The Nasdaq Global Select Market, but any other securities may or may not be listed on a national securities
exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of
the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open
market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities
sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market.
These transactions may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings into an existing trading market in
accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the
applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third
party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open
borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise
loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its
economic short position to investors in our securities or in connection with a concurrent offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific
terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will be described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for
which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_14"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP, San Diego, California, will pass upon certain legal matters relating to the issuance and sale of the securities
offered hereby on behalf of Exagen Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc152545_15"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2019 and 2018 and for the years then ended incorporated by reference in this Prospectus have
been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g152545g91e59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Joint Book-running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="bottom"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>William Blair</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Book-running Manager </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:13pt">
<TD VALIGN="top" ALIGN="center"><B>Canaccord Genuity</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Lead Manager </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:13pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:13pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>BTIG</B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021 </P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g152545g06a48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g152545g06a48.jpg
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M$>H:D[(MSVB(A[&Q":1D[O:%]!_30OIL=0N]E+5>[Q]6=Z]ZM) -=[*'V.:
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M4Z]'+:[M*JFX")_ 3VYQP+:80,@T=B/.9:<;::B$I,UMM4+$1$87.1/?8?\
MAVW/)^E1Q8DD\\G3+&XL#&]+FEP(!%WYCR)I>XU(&1D;8G$/<T [\.X-5VL_
M(G8+88RI2D8]6?.<?+.?S^,8^?\ S_\ SYAUDU[>$3A$X1.$3A$X1.$7 ($(
MPV*_-F/,1HL5IV1)D27D,,,1V4J<=?>=<SA#;332%...+SA"$XRI2DIQG.(;
M;Y!$P%TCA]AH!MQNJ'GO6P]52YS6-+WN#6-!+G'8- Y))X 72(N->6"S9L'
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M.M&Y$IL:ZT0D/L,0W&Y"D27'V4LY6I>,9K&-D/F^KLAD=.UU/BZ7>T;5@_9
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MEV9(EQ''VW508+N9K[6,4309<D#CC-<7.<UK:&UG<FSMQ1]P\ERSZ79?$O\
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M\JYOLZNS@(78@NDM_P"G"V@^R6Q&?K+3&#==CQ*1=  BNB@@87K&PH:^#_\
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M:2XQOA<R,,(Z>H]+ND5U;<?:M;3XFCTZ+1M%BCD'\V-U''C)8\U[#V4OM/M
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MT74T0:]+'NCHK]+&2R38EN(AK,",;\1V\(3C*+W'GRVF26*4M>YK@\AQ+Q=
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MM_=\UDMCZ9Z@L6M$:[77$"WH\&FQX=V"M0!MX8FZ^4,74RN;#&C(E/$!C@>
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MGM[%S<G;MV*U96K[D3;;3&MD;7 G;D0'L^PTBKFD  1HN(2:>#P6"%OD'BL
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M2TW1?HG^C?P]GLU31_!F@X>H1/\ :098PFSS8T@-B3$=DF88D@_=?C")[02
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M$F,4(?3MA+NPN_VN*4[=NDU1.W.PV H'F^-N;VYY%4F]RJS2D!VZKV<,1[
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M_3?#GZCG9T6G_21J>+@19F7D9,>%BLU#5VLQL1DTCVXT#6L8UL,(9&UK&@-
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M4\6?U[J_ I0_7OO\5ZF.AW7UB9.DJ'W&5&43AD*V'GW<].":_8:W-5-_D@M
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MZ [B_=Y'I;(MM7")PB<(G")PBH]W/['7WKZUKE='A5J7FV.6Q)/ZQ#Y\_#>
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M>-D9F5*R#%Q8)<G)GD/3'#!!&Z6:61QV:R.-KGO/9K254>Y;2-GY$J*,D.C
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M,K0AEORG#KF<YSG*&G$YZ1]''@0^,]2G=ER20:/IPB?FR14V7(DE+O8X<#W
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M_#I:DQ7%^,?/.&U2T.+S]B&TK7GPE.<XZS]#&HX^#XS;%D.:PZGIN7I^.YQ
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M(0A.,)3C&.$7/X1.$3A$X1.$3A$X1.$3A%\]OLP?^-J]MS_I T%_[CLKF_\
MB7^R?@O_ &&?_O8ZU;1O_'?$?^UQ/]V9?0ES0%M*<(G")PB<(G")PB<(G")P
MB<(J!>U!QG/2#<>,8SG/Q&M_ECYY_P *E*Y;Y7^3R?\ H_WVKA'\I?\ S+>,
M/]?P[_\ E&BJW.H?\$VK_P#1W2OZM#.>L?\ 5L_U&_@%UCPI_9;PU_Y!H_\
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MNB:Z-CG=,AZBXB^BW$G8?>=N*[K>?$F"(];\/96/*^.<9C(I6W3I871$RLD
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M6(MEF,P_/AO/P(["9#4K*68SC;?G"'7L8D95G"./):UD<L;H\J[<VB[[-&@
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M.&,O::_I!9!ORXJO6U>Z,ZIQ*?5CY^CSGS_?>?./MSY\??S$>?O*RH-@&JL
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M'QCWAB=$A1X0>*_&D.-1Y6""8KZ\-O+0K:O!V1AX.3F:EETYL&-*8F$UU3R
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M+0[62:F3U//*,XDDZ_ZV4/*:;C?/",90K/M/K@SO#TF'G/#LG"G9D8CG 6&
M%KHFT!9)-@@78&_"\HM&?BZ\W*@OZKEP.9E@7TAS22'NX ;5#[6UD@;FS77J
M[U%V9#]H';#<@:B9U&TOLW>.\-)'8LV)+%$-H;S&UJNV:M18\:4\Y'=H,T9;
ME)P\RA,>:4=4TM"WG4YR&I:WI\WA[%^JD_SEFPQ19I!!=[*)YICAOMN"=NP)
M-MI8K0L)^1K60]IZL+3\Z88LH!,3G=#02US0&D@@M<=R"TMW!%S'NJM;NK7M
M*+9M#7-((EW+OTB:U/03/O(K0O-^'[/DV4FU/=<>6Y#8#5_*23LJ3&3&6^[!
M@I6Y)EI;3819^))X6ATV5[&2/U:69[23UMB;"\,?1ZB!U@#L+(HWQ1K1U"'7
M)3I\3GY$N-T8SJ^S9%2N)HMID8<1VZND&K)436&E;V[6*ZMZ>9ZCW'K\)T3N
M>A;4NNV]D%ZK*=&MZ_E399(=2IP"9/)G2UVDR,N$"<A4&-);DR52U+>=7RC#
M=A:;BY9.09A/C.BB@#@19-]9LN_9(VL#;F^]TS#FRX\.%\0AEQ9&322MW'M0
M?MVX!HMQ+B>=ZI935['V9ZL]P.[]O&=.=N[GIF]]AT.R5"TTLM38 UR#7*'$
M!S5N(.&8DE>4S%J9QZ6<8RMA2O'SQG-[/'IVJZ+H43=0QX9\5\WMXGR?U?60
M0\AQ;R&_LBQ?!"]0[/T[6M4F=BNDAR((C#(!0<6!PH$-(.S@-B>!S>VX[2UV
ML&Q=>5JY6J@GM6GS424\2H5HD#I)ZO.LSGXK<4@^)D2A[CK[##4].8SZDXCS
M(Z%XPXE>,:;D1-9*6MD$@:1]H;@_F>!S5+:\6;VT(?T%G:B*KG_'WU?FI:YY
MJX&W^*]3F$^/.<XQG[<><^/GA*O'_/X^[[OO^SE-]/6; L59/HJ2+(\P=Z[;
M7O\ ):2NY]5V!VJ[W]?] ZNV*]K9SKE1[)V7MEQ9K8RW1Q5L-RHE)UE"<#%\
M8'.$,1_K86A9DX4MEGTR&DI<PASF[:%J.!HVB:GD9$+,B;,:W%CC]H&O$+@\
M2N% NK[3>J@+KG9:5K>'EZMJ^'BP.,46,3/)(6VULC>DQGRZOLFB30OBS2PC
MKOK^\]?N]N_>M.\-@9VN$[I:61M>#:9=6%U.$<N%49G478@9 (2KZ+3-D5*0
M#GD7&\Y<FQV8[CJ?6VZO/KGY^+EZ)I>=C-;!DZ1/[.-@=;Q&XM<US.^Q:#0!
M(LFA>]IIN!G8>M:CB93S-CZICN+Y""T%[16_86'2-NQP/+[, >SW!VG9/9W5
M_7B[1IT@#[+J-N\,MZ>R]\ 4MUJM)6HZCE1\.)PT\H3JB1(DP,JRY\,VY%=:
MQZL8=YD_$@Q\'3(LO%R8YI]?QX7Y/LY 7Q$-CZVR426DD2]331!?1V  M=$]
MIFZP<&:,_5=)=)+"*MCG-D<WJ!L;ASJ L[MNKLF5B>YZ]I'N9[4RQ'B4,5@U
M&ZO@H,Z=&=FPH")NK<1"5@(PV67WUA*V/3*)EG<,K9PU$4PY_='4H7C<LNR]
M!\-P8LK?;X[LAS^EP+HW.D+V]8LEMD"KJ[]Z\-2U*+ U;7L;V?\ WC*B@;!"
M6'K>'@M>]D8:7/:QMN/2UW(V *P2@C^NM,[G=0V/9UW6.?EV9^PP^TX769B6
M7UT0UA!JR%Q;A?($-]RNA;?]9$M+&RFF(I4E.)3DY;7X<PFY?-F/T75FZVR'
MVK987XKW='MW2N]M[0MY<YI^QOYV#8*KP68F%EZ1A^'Y.IN9DR2YP8XFG1L;
MU&0.+BPNMY(=0%[42 8QZG2O9@0"?9MWMT_HV)MZ-W+[ R&5[#DICV!%?:ML
M9\)(:0MYM?P6'VY;D-?I]*LXSG"<YSG&+W73KSXL Z*YYP?YMQA(&RQAG6.O
MV@-NZB:K;<\7ZQH!T2"7/CU)S6YTN9,7AQ=;QU4"T!W21U!QMHL_M"P!?TXU
M$H#*5T.4K$R'.KY 6/G YL-:'8DH3,ALOCI,5Q/G*V7X:VG65*\94VM*L_/.
M><REZQ+()=I>MW6#5]5[_>NF0&%T,;L>C%TMZ2#8JA[Z]Q66,KRO"LY5A7C.
M/L\??CS]W*%Z]Z[CD=PO=PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG!W!'FBQB;5P<\L,,S!8V88"MRT"B4F%'>(#43T-MS$09SK:Y$-,MIMM$I,=
M;?OT-M)<]6$XQA&71QNC!(:X[B]C1-6!SMV/'O5#XV/>V0M%MNO,7Y$5O^(Y
MM>L[5A)^+'8-C!Q9B!-8*PVRD)B>B*0A+P]%GL(D(<PU-BO)]]'E-IQ(9=\J
M:6G.<^89)+&9.DN D!::)%M<*(-&RT@[@[5VV2:*.;HZA^P0X;;=0WOF[!X/
M/KNJ7:4LH&5MCL]*N4H2BX4?:Z18B2>;C(* :.0H5+D"HPF7+QB5"KY*:DA)
M]$5Q,.44=(*QA;V7<\]7Y4GLFQ%Q#&7]D.VKS([FMZY-K2/#^3 [5/$PS#&,
M^#56MQA*![1N,88?8AI<2>AU. J@XDT/M;X+V04ZNHV?L[)I==DS=(5@N9U>
MW9PK3A(@;2TMETU/D9:25@A$QY+K8P6T^WF2MW)5]EM;<)6/5F5E8T$L<$YZ
M7,+Z::#G;?M#<G8U7Q-UM8^)Y93I^5XA.&7/TZ.23'PWL'5D/8X /<TT[IHN
M]FTG]HAVP*IH([2Y=N6E6]<:9TO6]KVJUCJ)N^S-TN$V0KMTL,L@."-#9T/$
M2>XV6S7S9G&'YBWW13L!SU)P^E6?'^<=2FCBA=D2N%ELC'R/,;"ZR.EEU1%6
M#YT3:YO%])FH99\/86E:)@8>;DZC'B:K[7%:?J63)D3P1;M +C)'C23M<'$&
M.B/LFUG5AVGLF90]U[NV34>N%N>TWL8IKZ</*:_:P;MD6KSA;4F,--%B!)Y@
MF2BD,10,'*)"<%5,L_)#F<8IAS]3PX7M;.]L74XN9'*]@+@:-!KJ%@ T19L#
MA9[/\4^((-,UWQ!E1:)EC0\V7%EQ/JA,F4V!D3BR-SNK[;A)_1M+2;.U$E;!
MNE=U?V-I.OW90>EUF!82)N>&JE)'MCH=7%.$I"8H8NRSE+.;)'RA>3^6F(Z&
MRBI+/H5EO+JX,LL]32/+_:"[<2YP[4223M^6RZ!X#UR;Q'X=QM7F&+'];=))
M'C8K:&+%U$-QYN*FCHA[0 &N)%"E<'A;DG")PB<(N,ZSZO*LYSGY^?3CS\\9
M^6?L^_Q]_CY?;C.,XX4;&VD6-K];7%;C):SY0UG'G&?/Y.?GY^W.?E_?9^_.
M/&?/S^WY\DDGDD[5\% 8QH(#0 39 XL*L'<P>8D=<-H* CI92>R%3/<&Q&5O
M3)P\?+C3BT:(TVE;KK[@R+*0RVA*U*<4G&$^K*>4.ZZ^P>-ZW/>_AW/PV]-;
M\7?6&:#G28<9DR&B-[6L!+G-;(UT@%<GHL]S0L<)7-P"]B4L0G43J+%++#8[
M#A*,T^@96TR8Z4NRBDE3.&VY<3*G,H&IQF8](;PRMMA*ENHIZI72=5G>JLT&
MT*Y-\=KVYOM=<&I>WTO%CTZ,N=.T,G=TEOL@YH#G/L#]D']D&W$4".3!FX+Q
M%ZR7WK4&6?= :O+D[\F_D)[>9#)J<JLRI\6:=G)9><7.G'W7"&7U+PJ1+]/K
M\M_+%3)90YI=U$#K#G$G<!I(\R#9NS[O5:OK^:_PSJ_AB&%SFZ9//E_S@?9E
MXD)Q97MDDZ0229^G<\.()H<1O<>_+XZTVJM5=BMDU8V%J\/0&?@R+DBR:]N8
MN+*-VK#2%)P\R.D.3([4Y*$PF%->Y=Q[Q6,8H=(\@N:+<U[1R22T[DWM5<WZ
M[K%:E](\^//JD&+CPO#,[ @P <>3^EQ9P?;RD[6(S3206T74;VJ#P'M&]N2*
MLFQNA=<V!+M"^N)=FMP;'[W7GP5SKP.1#N&9#\C.<F!):>4&+;;C*0X%G.Y;
MDQ4)D8I.6^P2 ;'42"XAE$-WX[.JN:H$786L8/TIZMD8+,IF-IDW5@^VE$#9
MWNQ*S8XG"?J^R.MA<6=)Y =^SSW6P_:,[+&3[!,I(^DR:B*N%C"C+#*BR7L&
MA8:G54U&R-;GE0D4HN46+$HKT@<06YB-#91!A3G?7G'E-D/9( QHZ":!(-.V
M!VON;J@5=ZO]*FN193(M/@Q),8Y<T8E="]WM&1QQ.N/J?$USB7FR'/<;/0QV
MP.W[5MJ?O5 IUOD,KC.V*O"33D94>3$4RX2C-25MJC2\)E,>E3F<8;?3AU.,
M8POY^?-V"2 2*) ->\6NV:;F29VG8F;(T,?D01RO8&EM.<-P [<"^Q'&X/"S
MW+;2%^KRG'GY^,_/YY^6/ECQ\L^/EYSXSG'W\'JO:OC?K]RO6D5= ;]S]]GW
M_>H$[-58_>=$;4JE28R_8+!23XT6PTM*5RIDD>^VQ$PK*DMI^*7G#&,K<3C&
M7<9S\O/*'>T#7>;FD"MOW>;[CS'G5<K!^)<;*R]"U*#3S_WQV,\8X:=R\;AH
MWV+B +YW6 Z^V;8=CZ_#0*C4;54SSHN*/,/W>KE*^Q4I266T3\YADXD99F5$
MQAS$5$!#HZ2\TVI<U,=2U8FY'.!>T@$;@\-H4!6]UVW]3P ;73-1FRM-Q,2'
M#EQY_9=&5))&&"!PC%BSL]Q<"  .X)(&RC+M=03U5ZU% NN2M['%?K" *FCM
M.'$3MH+*F6"%,L$\LR'FCC4J(3QEUHY($R?C(P]WTP&EHC-LIGI:&OZ2X. M
MIW-\[&J%'CC;98CQM@Z@SPP]NF3Y G$D;Y9,=CI)7L#[D#FQN:]W6+V82XD
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MGRE7CBZ6"J9^2V.(' ?K,1&C=@?#,-? QWU.N1_0_P"[8RXOF7TB7!BE>[-
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MB 5/8E(ZSVBKPH(9\[ B_P ISO4*;MK!K807=I,A735 ![]ND]^I['U)K5B
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M.-N]'<*VO4SMQN;>F\MATR[T6M5S7['\N+])?C2]?P+4%_D7WNO32!9D<)[
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M@6S51$PS6KS F=G!MLU%.4(F]QA9#:=-K&F8DT,;I&LQ_6 P*H1I=(GS;/8
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M/<-CZPU0(G6C<]G&RDVF^Z$=[!%R$R&)U&<917*S5(DJ!&D,39!&P%W8C"(
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M$I\0DFOS( Z%(E%-_#:MNW%GMS6_O[KRU-[.^QT\[3K#<'=2F'X.\5[DL N
M.(3!HJ$0T!V;H3=!J62E<96]7=?[ W_$8U_B:T,0S1:^^1S##&W6@*B%U]NU
M>O-V??\ BH?@^S4WNJG"]?$2&@HHVFG:+M81<1Y.YR[!LN]4SJ[IWK])T_M$
M#(H$*,SIRW$-<3RMKM$*S6$P4KS-+$*URB4"DRI1+%WOWNO4D]_+RH;[W:S]
MSHKV%F[4C;78E:7I)F][*CW[9\"L7N\'*Y6PL'83]H>U]$IMIU*_3-U,FA;L
M\Q7]C/ >O.Q=2;@N-[V2!,6Z(8CU2*2Q1!W\OSYV/SL #LI*Z@=-MP]>-LC#
MYXQKQO7PG2[='G0:O9[19W[5>I(#1HJ5:!E6O-$1+T[A"M6E6+<G7^U)50W"
M^Y4K;8M756T VWXQ02*K[ZKS\N;OO9%4#2C'3GL_]Y!-[4C:>VSVIC@:GV.C
MSI8H,:*$X)5BA"^UB!Y6K4*/J37M&UA!>/=@0!@)KP0S8<U60!.$2&S+R;GQ
MB.2DD=AS?WD'S-\<[>X+(NN_1;<>EK?URC%'=*FZ7J6SZ[V39+G%*VI.Q6;'
M3_9WL=')VO*;77Z&R(=ICY40,V'$MA"[!YK@V?/KCU!CRQT8T2(3=\]Q\+O]
M#[^RZ^\=!-T']ID++6+?1*F)N5VNI2W74?:+6Y9HE-/;EVUL8<"F:L.T:S:\
MOQJ #VA,BT&WC#VG;WI.\3K/:A5WV*(*0ZI )U#W^AXX YN^VXW!"_"'0[;]
M[IMC'W"N=6J)8OP->QO5VHIUK&LI"/\ 6'9>ONLE'H&QK'92= K9%>8#>CS3
M$@="K[I#7U373ZH",7I$2:3C$O?N=P=^=K_-==1?9S;'";5C6:S&J0=K52W.
M3V!6BA:_;"M9JT ;+VCC=D2/TA0B-3#TK7A\)*'08^$PRFRG+9<7B%P@V36T
M284K9@E_A7 \JYY/\/5=)8_9AWTI1Z/30EEU6 9K>BM7:U+-1X1K <O9J/I;
MV@&O3LF8+B 822E7M-A[9TA19F0["(EJN+O;4I$:=]#,%B!WG9WY[\C\O-;2
M-*5Z[@:N6D;$JNIJ5;++;[#:"5;TVX3)U:!])OLMQW"%M,UFD$[W:9S$1L@?
MMLND5%<J5*2,0(6R*;*$B@_'XJ7^%"<(G")PB<(G")PB<(G")PB<(G"*M_:?
M9.Q-5:VK5FUB+K!6P%-\]9->SH]L+3@XY-8VOV'UEK"SJCR(%>LCRB+X>W28
M,-Q4)M Q4M9U"YD@2P'*%( //D3\0"5KOH_M+MG5C5^JANU-/"SVWMA5#0QB
MDE1]VLLJNWX=MFF=BK2];;Q$UKH:VV'69%F'U?OLU56IVO\ 9HQ"[306'CHI
MB7;':8_BI+0+WV!/;R(]U\CR[K/3'M+;<S3;-?Q772") #CM J]9$;3VT:HN
MR;#9K/UBJG:"T5Z7JJLZ6V5>H)RI5^[@*2P#KPBY&YMNC6B;9QM$I5=<MDPG
M3QOV)->A(Y-#M?85Z[+W63VGWU4KL_8AG1,]K5Y<Y%UYJTW%ORRMRNNV3.N*
M'LFLUL[0@U#(KJ52-0;L^$5;QE@NAR$<K)5KZA2H<^OS"Y.GM>^_NH$CDGT7
MG([9:[[%4XE6-S]4:Y:<U>V];(K]+VJ,DGJ5(M>]^T]HZMUNUU9G;&GZX=F
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MMW?8IG6S$)R^[)U3V5NW:JF3]=$%W6:K5573L:Z8KY^MF8NTYQ7757K86%9
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JA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g152545g91e59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g152545g91e59.jpg
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M%18A(C%8%Q@9&B,YE[;7)"97=I66M]8R,SA"0U)U=WB8U?_$ !P!  $$ P$
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M13J3-:3;MC4FBDP0-JL D7)V<DD2N1&&RCYN=>!;:>/^TPL8.9*GM1[;XZY
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M)Q)5D9OE59>Y&3X:96*J=JV5WFME47NLQW;R%TM1SZ>;N#5&M%;%(L4^U94
M[$K%.GC)-,2VQF+R5'.V9\<9G+GLO-BM+=SA2UXQX4_3JG:V,^[6R5E+"X^_
M=^#$,1A+4YK$2IW">OI<0 L>.06/'MKVM;\M5]Y+MA<?7:!KU.I\499.[TV8
M8)&?H Z.I3*0!SP0!SJP=G.,8SG.?3&/SSG/Y8QC'[<YSU$^I,U7%Y[?44Z'
MXWV:=U5QKJ8_)#8\"23%SUN5.YAM.5N6'6MI\(.:CV#I78)H+[:FCVJ_B)K^
M//& [@42R4(Q+^UO2/*9B&*]F9VP].55>*OVNYD)HSY#-&Y5*BL#RAE[DO\
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M"E'1F7',8<6TPX4IIM:\86I",*5CUSGJ,K<(KVK-=6+""Q-"&/@L(I&0,0/
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MLM&:*0_4QPV.J+G]33R\:]?ZCV<ED:/[8%;2MUN"*U??YQ]O&<X8,E@*CH<
M5:\?]'+L<'(F):S^U*)1['[%]:>D$49R>]9N 95O58@?JL;6,H[ ?7AV1>?Q
M[8_#6_JI(XQ^T(N2(S3M2$?1G6#&JI/Z45VX_OSK,T!RZ[_U(T3IFGZ=X=0L
MGJ:L:KH$%K.51IHP_P"[4.,JL4)4Y99[=_&3(.RL$T#(/2&!V,G/$K+4TA3V
M4XTRV ]*K.4R5C([AECOS7K<MV/[05>W:>>1K$83X1N@1RED"=1Z0 O)XUG&
M9SU*KXZA!1P2/2AIUHZC_ ._762%!"_7\2.LO&%8MP.HGJX\Z5S^/']2-^Y;
M#_V('?XC=)_[&O1[_C'+_E)?Z%KN_9%ZJ_P G^3G_I6C^/']2-^Y;#_V('?X
MC='[&O1[_C'+_E)?Z%H_9%ZJ_P  )_DY_P"E:8!SFUSWL^X6G6G\8#A184/:
MH5;/PJ71=9KK9?M73%=^]#2;Q5KF/FCY75XMT1O"6/C.X)5C*_D*QAU[8N>F
MVTOC?LK<D9%[L=];5SO+S6[W;9 M>/I;[]PQ\]0Z?PTVMQ5=_P"Y_A/M/;\O
M-+O]EJU,Q-Q8[7<#DS2=0^Y0J/'!Y_$Z>?WOH2]UGM']LNM;/BI&"V-6T:DK
MMXAYA.$R\9:8/CN;%38<JG"EX3)L'B/H/3YJ\2\/8]<^G3=]-9:L^_=YSTG2
M6G-\?-6DC_<W@ERZR1M'_$*,.C^+QI>]08[,6RMI17$>.U$*45A)!Q(DT>+9
M)%<?V892&_C<ZG=[,@ D=VPN'XX3*!V7-=29ZT-IPE*BY6\6N3/>SC&,8\R3
MC"2'%?M4XZI6<YSG.<Q?ZB.S[UW S'DBXB G^QCK01H/^RBJ!^@:D;8:JNT<
M&%' -5F_[3V)G8_RLQ)_7J3OIEZ=VCHT:HJ]AL)FM=X7==>B4X$BP:7R/@&1
M6<>#28R+V/6_ABX0GTQAIE4>(I"/3Q3EE'ICU3CTLYZH,9O3[&S2?-(UC#RE
MC[];TYNIOUGK;_'JNWIRHBWUD(D^5%@RL8 ]NA+472/U#I7_ !:O5=5CU8G1
MT:-4!>\E_7@O?ZW<4?[K:XZM3Z??UL_\&SW^?N:K7OG^N'_A&%_S-35_KJJV
MK*:.C1KQL+^XR2T)_,*(<3AS_P I$JMM+J6\XSZ>3<:.ZV]G/HXTX84UXJ:)
MBUXZQ[G] _\ ,_\ ]>_\OZ-<O/?G('[E68!OPDL%0P7]*P(RM^^4RR+P5DKD
M:T7=.Y=?\?\ 6=JVSLV:;@ZA48]9IKWZ%FGE+SAJ.A(<13C>9";F35LQ\4"A
M:,OEOMX<<982Z^WI+*D*-)(>%4<G\3^  ^I)\ ?CI'W9NK";*V_DMR[@MK3Q
M>,@,LS^&EFD/RP5*L9*F>W:E*P5X01UR..2J!G6K_N#ACRK[MVH>0/+N4E3J
M#,G5UV/XE:F7EK EGJE8DW3S*V\:8AG(,=9 42L-%3R<@XLM[E2YHU<73QAQ
M3E;85ZA4W5B\WG*PGQ]>Q]RC]16H[?+#D.W[2?"2%9^GI/44,B+W(XM4UVIL
M?=7KIE,IZS;LC>E4B4P^F^VY/,/P=.9V29NXJ@PC[WX>SPGQ^7EEO\04Z]:.
M74_IX.X[(5^6([=&_I(R,-#/FW^/AUFR\$;$S CY9EPTG)).]M\0C!3<C/TX
M(M#3PYZ+)6LN9>?K,4B;O5O:"2QC=^*175EB&66#AEDC8*M?)(4Y##I*16&4
MD%##-QP)I#/GIANIHG.ULD[(RM(<8TW*LC@LT^/?JX*GJZI8%8 AA-$3R8D#
M.>Z%!7GMH=Y>M<OZS"$$TZ^7>$Y"5C#7D.+9&SFF:_O>BJD?'V6I64+)LN#,
M)QER/A[S F/(7\E&77#LF6KO/T[FV_-*!8JUI,3/S\S0E29<7:">YC15AZ?H
MTE6501T^$+=\=C:>^XLY#&3!9L1Y.'CPLO4!%D:_7[!W8S=7U6.Q&Q!Y\W;]
M(;LUIR+U52MT:ALP-MU]?H4::@9<)Q&5I0[C*"XR3&PI3L9.PQJ"(J=AR\(-
MB980N/,:;('<3BMF3QMS$7K..R$+5[=60Q2QM[<C\UT;V>*12'BD7E9(V5U)
M!&K X_(5,I3KWZ,RSUK,8DC=?T^Z./=)(VY22-N&1PRL 0=*MUPZ[-(=R/Y#
MZNXJZ9O.]=PV >OTFBQ#\@2I;K.)&;DLH4F(J]>%=<:S)V2QG^S%PL<VK"GR
MWTJ=6R*T00RIX?$7LYD:N+Q\1ELVI @\'HB3G[R>9@#T0PIR\CGV4> 6(!3\
MKE*>&H6,C>E$5>NA8^1UR/\ O(8E)'7+*W"1H/=CY( )'SQ>'^Y[3R*[Q&@]
MZW1.&K+MCF34+S(AH6IT>+3/W=@T"%"<6A"U1L''."1$9E:<*^WA#8S^?Y]6
MUW!CH,1Z?97%U_,-#;MBLC$<%^U5*M(PY/SRN&D?S^<QU6'!7YLIOG&Y&?Q+
M=SL-AE]PG<G#+&O@?+&G2B>/S5&IL/JAN+T\4_H3F-7(X@N)AXHC1>R#16EJ
MS!I^[R=OUI)$Y9PI301LA,WB)(D'_:8&D5U\##JB)05KJ-O1/-Q*,IMZ9PLD
MCC*4U) [A[:5[J#GW=4CJR*@Y)03/P!&QT__ %>Q$A.-SL2DI&AQUIE!YC^=
MYZCGCV5F>PA8\ .8EY)<#4ZO:PYW4_GAQ5H]W'G W=O4J%A:;O6JJ(;3,0U[
MC0$B/V)8.5>\FNWS ;MFKIR,/"*02="J+<EH&78&C'?&U[&U\Y9K&)AC[,DE
MC&3\'MR57<L(0_''>J]0AF3PW*K)TB.6,M(FSMQP;CPU>P)%-ZO''!D8>1UQ
MV40*9>GW[5GI,T3#E>"T?47C<"2;IG:=>L*3DXZ%CI"8F) *)B(D(J2E)22*
M8!CHV.!8<*-//-*<:&#"#&:=(**(=;8'8;6ZZM#:%*QLB/(ZQQJSR.RHB(I9
MW=B%555069F8@*H!))  YUJ[K&K.[*B(I=W<A515!+,S$@*J@$DD@  DGC7S
M;N\US7AN<7-&S7FAENGZ=UK#":@U3*^#K0UDAJT?(R<[;F&G$H]&[-9YV5.C
M%N(;-<J^*U\]D<A&1VKA^G>VY-L[<AK6E"9"Y(V0O)X+0R3*B15R1]88(D5P
M"5$YFZ"5^8U5WYGX]PY^:Q68M1J1K1IOP0)8X69Y)P/PEFD=D]F,/:Z@#X%C
MOOC\5YO>G; T)N&H1CTK9N+]9I%UE11F5$%JU=::'!0NP"1FF\9<SB%,!J-H
MDW?7VA:_7YHQ['B/A:(@],\Y%C-[97'V'"0YN:S6C8GA?CH+4LE0,?;[Q6L0
M(/=I98U'OP93]0L/)D=H8V] A>7$15[#@#D_!S5HX[) _P"398)G/LL44C'V
MTZ?L/<VZ=R=X6:_U*7-AM;GXS5F'UA;ZL^2VF3+H]>:3$:XND:,M7OF0A58'
MC*](F)\U"6:&D6BTL,G1+AJ'ZH;;L87<=N^L;''9J:2]7G"GH6S,3)<K.WLL
MBSL\JK^^AD0KR5<*L>G.X(,O@*U)I +^(BCISPDCK:O$.BI.@]S&T(6)C^]E
MC8-P&0M-YU&NI!T=&C4$]Q[YFN7.< 7"#06B[+R'M)M[B-;HO]6O</#U)5G<
M\57!T=*J_-/$US7K:))=FL2'TAH;@)TL5#L<&R<7)U?TRN?L:;<N4R<.)@6K
M)<-6>M))8[ _V.#][&!-;)001<=1,L2MP[%5CJ?U#J_LA7;^-QTN4F:S'4%F
M&RD</>/[N1]U(6BJCK,LO/3Q'(PY10Q:W]4G_P!E/CE_\A"/^'%MZ7/1'_;W
M+_\ 5(_TR#2/ZP?[38K_ *S/^BS:E-[.7]61P\_]KE_WIL73']0O]VFX?^G?
M^C%IX[%_W)8+_H?_ *TNI+^F;IV:.C1JC#V._P"NAWQ_Z+R?_P")$1U9KU+_
M *W.+_YS"?Z')JO'I]_N^R/]YF/]*35Y[JLNK#Z.C1JA#WN]4<@RNZQL3:6L
M=+[0N0<$+HB>@)Z UK<;/6RY6L:]IA*6OGPT4^&8V-) _'.'9+PM"VWAUJ:<
MPKQM+Z;7L2-BU*-W(TJ[2G*0S12W*\,RQSV[*D],CAE+(_4I*\<$$<C5;_4"
MEE#O*U<IT+DZQC&RQ2Q5)YHB\-6N1\R(5;I=>& /N"#P=*S_ "U'>\_=I8_^
MI^V/_P!3KA_)QZ:_PP?\NT?_ (:[?V?>H/\ !(_R+=_^>N*^]9WN6\84YQL&
M0G*D(PI?%':R<96ZM+;:,95*XQE3CBTMH3^U:U)2G&59QC)^3CTU_A@_Y=H_
M_#6#O_U 'DXI0.0.3AKH\L0JCR_N20 /J2 /)U)_VKNY7S'VC8=Z&<_:;&:4
MTYJG5";P'<9C4-RU@T38"+9'A&MO2=C));G9*1;D"5C0<2,J3D9,AIH 5YYU
MD9<>^H>V-I;<QM&U@LA\3++;:*R&R->YT0B%W#]$*@J3(%'4?!)Z0.2-+^W-
M]7<?4S.1WJT&#P6&QS7I\C;J3TD$C6%#EI)2QGGL/*W;KPHT]BQ(L<$;R.D9
MWVK5G8O>!W7'[,O\;/43@)J*PD_@*F&+>CI/<]ACW5BDR!_QW<87\C"7!9^6
M%>=&K,4X_2ZP6Y/FVBPC0DJODI1(X9*<9^1#X,I'U/Z_J?8#Y5^;J;4$XVAG
M/ZJ'=L.X,U7N8?T6VO>D^QL5*7@L;KO0,8WFGZ&'5U_-'=LQLR8^LSXG'R-=
MFR%Z.?V,C(Z%C8^&AP XJ)B01(R+C(X9D./CHX%AL4( $,=#8XH8@S30XPS#
M:&6&6T--H2A*<86    !P!X '@ #V &KJUZ\%2"&K5ABKUJT,=>O7@C2*"""
M%%CBAAB0*D<44:JD<:*$1%"J  !JGQWW^V-L:G[EK?/?AY4+>;,V>VQ)FU*Y
MJR'EY&UU3;$>0B2K>X:W&UL8B39:L!0#7XF-!';7&7,0*PONDE6PYX&PGI?O
M6G/CIMK;AL5TC@KR+1FO21I!/0=2DV.F>8A#VE8]E7/#UF:$ + H:$O4;:-N
M"_%N3!03M)-.C7(J<<CSPW5(>*]$L0+@2E?OF4#HG59"6,S%9/*30*YWM>WE
M$4KEQK*]Z5Y!48A,7*6"=U_,T^Q4W:D9&(9#V?1H^R1T.B:H]^CG$$6"L-.(
MBUN.3%9^6))UZ#L8K*LVYO3;=LEG 7:N2Q-D%TBBMQV(;%%WY:E:>%Y#'9JN
M.(IR.OQ'-TLDTL+.ZO6B]0-L)7S=.SC\G7(1Y9*TD$L%U$ 6Y765$$E>ROF6
M$?+YDAZE>..9:_PG'KO1]F.[V(C1\9<K[IZ0DEGGR6M:V;N32MR&92EIJ7ME
M!;".GM?S61&11#YDJ-JLNC+2(V.M4I&(:>(E5LMZ<^HM:$9-Z]3(H@54N3+C
M\C78GDQP6RRQ6X^HLR1AYTX)=X(W)"QHN+W[L.Q*<<D]FB[EF>I";]"PJ^TD
M]8*\E63I #2%(7''0D[H 2M@/U%W<PF6DU6'XFZ=D+TXG B?MVJ]ZGEY*5_1
M86W56-BNF9*RK\TLY+6U[WY984W_ $/2:WI%LR,]^3/9!*WYWSWL8J]/OYG-
M,+T\?7IYX^O/G2@OJENR3[E,+0:S^;\M/(LW/M^XBT6ZN?8=7'/T^FMMUIV_
MNZ7W=MHU+9?<;LMVTUQVK<@B4#I4[%C4*:?#7G&2H;6NFF1V':Q*28GC'F[$
MV'&(F&XYYM]AVWY#Q&H\+FZ]C[!I6*>T(:V1R\R&-K,3FU&&X^62YD2Q$\:-
M\ZU*C]LN""*_5UZ]JFV=X[VN06]TS6*.+B<.*\J"M(4Y^:.I0"@PNZ_(;5I!
M($((,_3T:\NX<"=Y43OL:WMVI^+6U8CBYK_>7&4>LW6O:WM;VKX*B4;7&KH,
MHINVHCGHE49!KB#!)64)D75)-#-7(DK+P0O.]?=.,M>F-RO?SE&3-V\9FC-6
MFN0"[+:M7+TBJ8.L2=<O<5D14'RLH10O UK-MO(UO46K/2P]Q,/6R&*$-B*K
M,:<=:O4J1DB?I*=$?05=RY^96ZCU<ZN(;<U-KW>NM+IJ#:U9 N&O=@01=>M-
M>D4K]@Z/*PE27&7V5-D@2(!38\C$RH+P\C$2H@<G'$C'"#OMU]H7[>+NULA1
MF:O;J2K-!,G'*NOT(/*NCJ2DD; I)&S(ZLK$&<KM*MD:EBC<B6>K9C:*:)_9
ME;Z@^ZLI ='4AD=5=2&4$4KM]=H7N-=M'<QN^^WC:-A;+HXKA:X:7UI\8_;4
M- OOI*Q4-D:K^,0)LV-0IIA"UP<!9X2;=!:E)2K5LCX@3=C<7O\ VAO+'+BM
MVP5*=ENGN1W.I:$DH'3\13O<AJ3^3^ZRPR1ABB3S+U,8#R6R-T[3OMDML36K
M=<$]MZG#78XR>>Q;I<$6T' Y,<4T<A4.\,1Z5'L1'U#7= U\RBG;*XQ:RF[>
M'C ?RK-J'<%-LY1:,80I<O!1UPC0%EJ=QG*V8N%A&L9SX('1^77F_I+LFV38
MIYJ['7;YNF#(8^Q JGR!'*]=V"@?5Y)3]>K6Z>I^[ZH$%O$TY)Q\O5-1O03,
MW\>-)T4M^A(XQ^@:SB&^^+WFR0Z#=X.1XW\99@L9RV$KI4_IG5),3AU#KKZQ
M+"6;LW<24I0E4?6V9J?K&9<<1T]R!RAR7&T4^F?IVK6ZTJ9G,QJ1 !9AR-Y7
MXX #0JM+'_QYC'%/VV8()01&V[#U"WX5K6(FQ6)=AWS\/+0IE.022LK-;O<?
MO8A))#U@%NV07#6.^5Q8TYPDD>&7&'3Z%O(J&D[5:[=.'H839+M9KA=W0CKQ
M8_CX\?F39=6," &1E8\5#P\=!!+4'%,>BYZ99S([E3<6:R' ^(R4$%>).>S6
MAKU@RU8>?WL2SJS,?,DDCRM\SG2/ZAX>AM]L#B*/)[%"::>1N.[8FGL=+6)>
M/WTC0LJK[)&B1K\J#5\W757;%T_1*798T8UH?6M8J]@B),5DL,MMFK@Q,K&R
M 1*'&"1GTI?%+%?;6R\TMQIU"D*4G-7;DY;(6K,+LI:Y//%(C%64F=I$=&4\
MAAX96!Y!X(.K&U8>FC6@E4,!4AAD1U!5N(51U93R"#Y!4\@CD'53+F5V1^5'
M$S=KW+'M362PMAB2!LZQK"M6!F(V5KK)KF7Y*$J>9A]$1LS79"/<8_"4P\3.
M+CE#P!<+=&??/S.^W?4G!Y[&C!;ZAA+,BQ&[-$9*=OI'"2V.V#)2MCP?B(P(
M^OF59*QX74+YWT_S.%R!S6S990JLT@J12A+=7J\O'#W#T6ZI\KV7+2=)$;1S
MCEM:A!_4!]R_1HJ:7R3X914U;XQ*07)2R:]VEINSG$-^C:B)R'<',A7C'7/5
M2OL4%7@58RG# 2,?J5TR^E.S,FWQ.&W%)'7?YPD-NCD854^>(I 5E"@?VV69
MO?ECKGC]2]V8]1!E<$DDR?*7EJW*,S'\9$X,98_\G%&OX+K6KKSD[X/=!CR-
M2Z'T!8-):SM3:HJP6'7U1L]!C3H4S'MFB6?>VR)% @(:AUN9+!I9M<E):/P_
M'J EV2'@R?:MMGTTV4XOY3*PY*[ >N**W8@M.DB^5:#%TT+.W('2]E9DC<A^
MJ,@,OE8W#ZA;O4TL;C9<?4F^266K#-65HV\,LV1M, J\?G+7:)W7E>EPQ0S?
M=IKL\T7MY0Q>Q[Y+1.S.3ULA_M4U;X\9_%6U]!E9:>.J.NTR# \@^DYYIK$]
M;I 0"3FVAQPA(R$C?FBR4:[\]0;6[9!3JI)2PD$G<BKN1W[<J\A;%SH9D'2"
M>U71G2(DLSROTLDA;+V-6VQ&UJRZ6\O,G1).H/9K1G@M#5ZP'/40.Y.RJ\@
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M+-J39D4)*?<'WF60(J'8;8;C@116\ORAE8,X2 U^>79N>'[LI8LQ)YC<<\^
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M=?Q8RZB7,04&1,6=FKV@$T9@"(RO4Q1 Y$;RDCHED<],:,9 LC*A*,_0/E)
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7%54D)X\R*JJJO^<JJH!  UD]&O37_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
